[Pathological consequences of excess of interferon in vivo]

Pierre Lebon; Yanick J Crow; Jean-Laurent Casanova; Ion Gresser

doi:10.1051/medsci/2019037

[Pathological consequences of excess of interferon in vivo]

Med Sci (Paris). 2019 Mar;35(3):232-235. doi: 10.1051/medsci/2019037. Epub 2019 Apr 1.

[Article in French]

Authors

Pierre Lebon¹, Yanick J Crow², Jean-Laurent Casanova³, Ion Gresser⁴

Affiliations

¹ Faculté de médecine Paris Descartes, 15, rue de l'École de médecine, 75006 Paris, France.
² Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, Royaume-Uni - Laboratory of Neurogenetics and Neuroinflammation, Institute Imagine, Paris, France.
³ St. Giles Lab of Human Genetics of Infectious Diseases, The Rockefeller University, New York, USA Howard Hughes Medical Institute, New York, États-Unis - Lab of Human Genetics of Infectious Diseases, Inserm UMR 1163, Necker Hospital for Sick Children, Paris, France Paris Descartes University, Imagine Institute, Paris, France - Pediatric Hematology and Immunology Unit, Necker Hospital for Sick Children, Paris, France.
⁴ CNRS, Paris, France.

PMID: 30931907
DOI: 10.1051/medsci/2019037

Abstract

In this brief review, the authors present a history of the different aspects of the scientific puzzle leading from pioneer animal studies and astute clinical experimental observations to a mature appreciation of the deleterious role of excess of a type I interferon in human pathology.

Publication types

Historical Article
Review

MeSH terms

Animals
Antiviral Agents / adverse effects
Antiviral Agents / metabolism
History, 20th Century
History, 21st Century
Humans
Immune System Diseases / etiology
Interferon Type I / adverse effects*
Interferon Type I / physiology*
Lupus Erythematosus, Systemic / etiology
Lupus Erythematosus, Systemic / immunology
Mice
Models, Animal

Substances

Antiviral Agents
Interferon Type I